Global Acquired Aplastic Anemia Market Size By Type (Diagnosis and Treatment), By Application (Hospitals, Clinics), By Geographic Scope And Forecast

Acquired Aplastic Anemia Market Size And Forecast

Acquired Aplastic Anemia Market is expected to develop revenue and exponential market growth at a remarkable CAGR during the forecasted period i.e. 2024 to 2032.

The Acquired Aplastic Anemia market size growth is majorly attributed to the increasing prevalence of blood disorders, raising funding, healthcare insurance coverage, and awareness programs for blood disorders. The Global Acquired Aplastic Anemia Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Acquired Aplastic Anemia Market Definition

Acquired Aplastic Anemia is a rare, serious blood disorder, which is characterized by failure of the bone marrow and its inability to produce blood cells. Bone marrow is found in the center of the bones and appears to be like a spongy substance. It is responsible for the production of red blood cells along with other blood components. Aplastic anemia has two manifestations, i.e. Acquired Aplastic Anemia and inherit aplastic anemia Acquired Aplastic Anemia is more common, and sometimes it's only temporary whereas, it is a rare disorder as compared to inherit aplastic anemia.

Various causes of Acquired Aplastic Anemia include toxins, such as pesticides, arsenic, and benzene, radiation and chemotherapy treatments, infectious diseases, such as hepatitis, Epstein-Barr virus, cytomegalovirus, parvovirus B19, and HIV. And autoimmune disorders, such as lupus and rheumatoid arthritis. Sometimes, cancer from another part of the body can spread to the bone and cause Acquired Aplastic Anemia. The disease occurs mainly in children, teenagers and young adults. The supportive treatments of this disease are available, which depend on the severity of the condition.

Global Acquired Aplastic Anemia Market Overview

An increase in the prevalence of blood disorders is anticipated to drive the global aplastic anemia market. For instance, according to the Centers for Disease Control and Prevention, in the U.S., haemophilia A affects 1 in 5,000 male newborns and about 400 babies are born with haemophilia A each year; an estimated incidence of hemophilia is 1 per 12,000 annually. In addition, an increase in awareness about aplastic anemia and blood disorders is likely to fuel the growth of the global market.

For instance, The Aplastic Anemia and MDS International Foundation, NORD - National Organization for Rare Disorders, Inc., and CancerIndex, among others, are spreading awareness about aplastic anemia. In February 2019, The Aplastic Anemia Trust spring awareness Campaign was launched. Furthermore, increasing government support for research & development, changing lifestyle, and rapidly developing technology is expected to fuel the market growth during the forecast period.

Moreover, the Increasing prevalence of rare diseases, rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R&D, and availability of funds drive the growth of the market. However, the high cost of the treatment may slow the market growth during the period. The cost of treatment is a major factor influencing the selection of the treatment. The cost of a bone marrow transplant is more than US$ 300,000. Thus, the high cost of the treatment is likely to hamper the growth of the aplastic anemia treatment market.

Global Acquired Aplastic Anemia Market: Segmentation Analysis

The Global Acquired Aplastic Anemia Market is segmented based on Type, Application, and Geography.

Acquired Aplastic Anemia Market, By Type

• Diagnosis
• Treatment

Based on Type, the market is bifurcated into Diagnosis and Treatment. The Treatment segment is expected to inflate the market growth.

Acquired Aplastic Anemia Market, By Application

• Hospitals
• Clinics
• Others
• Acquired Aplastic Anemia Market By Application

Based on Application, the market is bifurcated into Hospitals, Clinics, Other. Hospitals are anticipated to become the fastest-growing market in the forecast duration.

Acquired Aplastic Anemia Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of regional analysis, the Global Acquired Aplastic Anemia Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America dominate the global Acquired Aplastic Anemia market owing to well-developed technology, increasing patient with blood disorders, increasing prevalence of cancer, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Key Players

The "Global Acquired Aplastic Anemia Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Pfizer Inc., Bayer AG, Novo Nordisk AS, Shire, SOBI, Octapharma, CSL Limited, Amgen Inc., GlaxoSmithKline plc., and Bluebird bio. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In June 2021, Heartseed and Novo Nordisk will enter into a global collaboration and licensing agreement for stem cell-based heart failure therapy. Except for Japan, Novo Nordisk will have exclusive rights to develop, manufacture, and commercialize HS-001 internationally. Heartseed will retain the exclusive rights to develop HS-001 in Japan, while Novo Nordisk will co-commercialize the product with Heartseed in Japan on a 50/50 profit and cost-sharing basis.
• The Food and Drug Administration approved Novartis AG's Promacta as a first-line treatment for aplastic anemia in November 2018.
• Mergers and Acquisitions
• Amgen announced on April 16, 2021, that it had completed its previously announced tender offer to buy all outstanding shares of common stock of Five Prime Therapeutics, a clinical-stage biotechnology firm focused on immuno-oncology and targeted cancer medicines, for $38.00 per share in cash. After subtracting relevant transaction fees and expenditures, Amgen will pay approximately $1.9 billion in total consideration to complete the tender offer and subsequent merger.
• Bayer acquires Asklepios BioPharmaceutical (AskBio) in December 2020 and introduces a new cell and gene therapy platform within the Pharmaceuticals Division. Bayer is now one of the industry's leaders in this rapidly expanding field.
• In November 2020, Novo Nordisk A/S announced the signing of a formal agreement to acquire Emisphere Technologies Inc. (Emisphere), a drug delivery firm with proprietary technologies, such as the Eligen(R) SNAC technology, that enable therapeutic oral formulations.
• Product Launches and Product Expansions
• Promacta, the first-line treatment for aplastic anemia, was approved by the Food and Drug Administration (FDA) in November 2018. Novartis AG introduced it. Novartis AG recently gained permission for Revolade, which is used to treat aplastic anemia in adults.